| 82.29 Delayed Data As of Mar 22 |  -0.66 / -0.80%Today’s Change | 52.83 Today|||52-Week Range 83.45 | +7.70% Year-to-Date |
| Previous close | 82.95 |
| Today’s open | 82.91 |
| Day’s range | 82.02 - 83.45 |
| Volume | 10,152,269 |
| Average volume (3 months) | 12,413,475 |
| Market cap | $210.6B |
| Earnings growth (last year) | -22.24% |
| Earnings growth (this year) | +7.80% |
| Earnings growth (next 5 years) | +7.79% |
| Revenue growth (last year) | +6.17% |
| P/E ratio | 35.5 |
| Price/Sales | 4.82 |
| Price/Book | 7.92 |
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | -0.24 | -0.26% |
| PFEPfizer | -0.50 | -1.18% |
| ABTAbbott Laboratories | -2.09 | -2.61% |
| LLYEli Lilly and Co | -0.01 | -0.01% |
| Next reporting date | April 30, 2019 |
| EPS forecast (this quarter) | $1.06 |
| Annual revenue (last year) | $42.4B |
| Annual profit (last year) | $6.2B |
| Net profit margin | 14.65% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman, President & Chief Executive Officer Kenneth C. Frazier |
CFO & Executive Vice President-Global Services Robert M. Davis |
Corporate headquarters Kenilworth, New Jersey |
